Compare TJX & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TJX | VRTX |
|---|---|---|
| Founded | 1962 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | EDP Services |
| Sector | Consumer Discretionary | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 146.6B | 135.6B |
| IPO Year | 1994 | 2006 |
| Metric | TJX | VRTX |
|---|---|---|
| Price | $136.64 | $547.61 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 23 | 32 |
| Target Price | $167.85 | ★ $595.36 |
| AVG Volume (30 Days) | ★ 4.5M | 1.5M |
| Earning Date | 11-18-2026 | 11-02-2026 |
| Dividend Yield | ★ 1.40% | N/A |
| EPS Growth | 14.32 | ★ 836.54 |
| EPS | 2.55 | ★ 10.90 |
| Revenue | ★ $29,078,407,000.00 | $2,488,652,000.00 |
| Revenue This Year | $6.01 | $10.46 |
| Revenue Next Year | $6.22 | $10.53 |
| P/E Ratio | $53.68 | ★ $50.25 |
| Revenue Growth | 6.04 | ★ 46.20 |
| 52 Week Low | $122.81 | $412.27 |
| 52 Week High | $170.00 | $568.67 |
| Indicator | TJX | VRTX |
|---|---|---|
| Relative Strength Index (RSI) | 45.22 | 57.23 |
| Support Level | $122.81 | $461.04 |
| Resistance Level | $162.72 | $561.54 |
| Average True Range (ATR) | 3.45 | 17.62 |
| MACD | -0.94 | 1.47 |
| Stochastic Oscillator | 14.70 | 63.56 |
Founded in 1987, TJX Companies is the world's largest off-price apparel and home fashions retailer, operating more than 5,000 stores across nine countries. In fiscal 2026, the company generated roughly $60 billion in sales. TJX operates through four segments: Marmaxx (61% of sales), HomeGoods (17%), TJX Canada (9%), and TJX international (13%). Its off-price model emphasizes branded merchandise at meaningful discounts, driving high traffic and rapid inventory turnover.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex is focused on diversifying its portfolio through Casgevy (gene-editing therapy for beta thalassemia and sickle-cell disease), Journavx (non-opioid pain drug for moderate-to-severe acute pain), and Palsonify (for acromegaly). Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases, cell therapies to deliver a functional cure for type 1 diabetes, povetacicept (for IgA nephropathy).